(Q44264051)

English

Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 December 2017

Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen (English)

1 reference

Europe PubMed Central

1 December 2017

Plasmodium falciparum

0 references

1 reference

based on heuristic

inferred from title

Patricia Bourguignon

6

1 reference

Europe PubMed Central

1 December 2017

D. Gray Heppner

8

object named as

D Gray Heppner

1 reference

Europe PubMed Central

1 December 2017

author name string

Pascal Mettens

1

1 reference

Europe PubMed Central

1 December 2017

Patrice M Dubois

2

1 reference

Europe PubMed Central

1 December 2017

Marie-Ange Demoitié

3

1 reference

Europe PubMed Central

1 December 2017

Babak Bayat

4

1 reference

Europe PubMed Central

1 December 2017

Marie-Noëlle Donner

5

1 reference

Europe PubMed Central

1 December 2017

V Ann Stewart

7

1 reference

Europe PubMed Central

1 December 2017

Nathalie Garçon

9

1 reference

Europe PubMed Central

1 December 2017

Joe Cohen

10

1 reference

Europe PubMed Central

1 December 2017

language of work or name

0 references

publication date

7 January 2008

1 reference

Europe PubMed Central

1 December 2017

1 reference

Europe PubMed Central

1 December 2017

26

1 reference

Europe PubMed Central

1 December 2017

1072-1082

1 reference

Europe PubMed Central

1 December 2017

8

1 reference

Europe PubMed Central

1 December 2017

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Specificity of Protective Immunity produced by X-irradiated Plasmodium berghei Sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

CD4+ cytolytic T cell clone confers protection against murine malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Peptide-primed CD4+ cells and malaria sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

A subdominant CD8(+) cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Interferon-gamma-independent CD8+ T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242–310 from the circumsporozoite protein of Plasmodium berghei

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Characterization at the single-cell level of naive and primed CD8 T cell cytokine responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Use of overlapping peptide mixtures as antigens for cytokine flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Optimization of intracellular cytokine staining for the quantitation of antigen-specific CD4+ T cell responses in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Monophosphoryl lipid A activates both human dendritic cells and T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Dendritic cells initiate a two-stage mechanism for T lymphocyte proliferation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Relative efficacy of human monocytes and dendritic cells as accessory cells for T cell replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Antigen-specific interaction between T and B cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Antigen requirements for induction of B-memory cells: studies with dinitrophenyl coupled to T-dependent and T-independent carriers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Characterization of canine humoral immune responses to outer surface protein subunit vaccines and to natural infection by Lyme disease spirochetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Cross-presentation: a general mechanism for CTL immunity and tolerance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Duration of antiviral immunity after smallpox vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

TNF inhibits malaria hepatic stages in vitro via synthesis of IL-6.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

The p70 tumor necrosis factor receptor mediates cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

The two different receptors for tumor necrosis factor mediate distinct cellular responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Activation of dendritic cells by human papillomavirus-like particles through TLR4 and NF-kappaB-mediated signalling, moderated by TGF-beta

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

Immunization of man against sporozite-induced falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.018

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.12.018

1 reference

Europe PubMed Central

1 December 2017

1 reference

Europe PubMed Central

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44264051&oldid=2108988162"